Robust anti-tumor immunity through the integration of targeted lipid nanoparticle-based mRNA nanovaccines with PD-1/PD-L1 blockade DOI Creative Commons

Chengyan Jin,

Yan Zhang, Baofeng Li

et al.

Materials Today Bio, Journal Year: 2024, Volume and Issue: 27, P. 101136 - 101136

Published: June 22, 2024

Tumor mRNA vaccines present a personalized approach in cancer immunotherapy, encoding distinct tumor antigens to evoke robust immune responses and offering the potential against emerging variants. Despite this, clinical advancement of has been hampered by their limited delivery capacity inefficient activation antigen-presenting cells (APCs). Herein, we employed microfluidics technology engineer mannose-modified lipid-based nanovaccines for specifically targeting APCs. The encapsulation process efficiently entrapped cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) agonist along with antigens. targeted (TNVs) exhibited narrow particle size distribution, ensuring consistent efficient delivery. These TNVs significantly enhanced gene expression mRNA, facilitating antigen presentation activation. When compared non-targeted nanovaccines, outperformed terms Furthermore, combination anti-PD-L1 antibodies elicited synergistic anti-tumor effect. This was attributed antibodies' ability overcome suppression cells. Our findings suggest that treatment most memory results indicate integrating checkpoint inhibitors or other immunostimulatory agents may be crucial enhancing response.

Language: Английский

Optimization of lipid assisted polymeric nanoparticles for siRNA delivery and cancer immunotherapy DOI

Song Lin,

Houjin Jing,

Xiao‐Jiao Du

et al.

Biomaterials Science, Journal Year: 2024, Volume and Issue: 12(8), P. 2057 - 2066

Published: Jan. 1, 2024

A siRNA delivery system was developed using clinically approved mPEG- b -PLGA, cationic lipid and ionizable for cancer immunotherapy.

Language: Английский

Citations

8
An Iron‐Polyphenol Decorated siRNA‐Encapsulated Nanomedicine Multifacetedly Promoted Macrophage Phagocytosis for Synergistic Ferroptosis‐Immunotherapy DOI Open Access

Boya Yu,

Zekai Xiao,

Shuaiqi Shao

et al.

Advanced Functional Materials, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 26, 2025

Abstract Macrophages are vital components of the innate immune system, capable directly engulfing tumor cells. However, cells can cunningly evade recognition and phagocytosis by macrophages. In light this, an iron‐polyphenol‐decorated poly(ethylene glycol)‐poly(lactic‐co‐glycolic acid (PEG‐PLGA) nanoparticle has been developed with efficient siRNA encapsulation (NP siCD47 @Fe‐TA) to trigger ferroptosis in cell also elicit macrophage‐mediated immunotherapy. The Fe‐TA (Tannic acid) shell NP @Fe‐TA induces cell, which consequently produces oxygenated phosphatidylethanolamine 1‐steaoryl‐2‐15‐HpETE‐sn‐glycero‐3‐phosphatidylethanolamine (SAPE‐OOH) membrane achieve surface exposure calreticulin (CRT). Meanwhile, encapsulated efficiently down‐regulates CD47 receptor membrane. SAPE‐OOH CRT down‐regulation remarkably promoted macrophage elicited systemic anticancer response. Eventually, suppress growth. Moreover, after combination checkpoint blockade (ICB) antibody, inhibits progress metastasis cold triple‐negative 4T1 breast cancer model.

Language: Английский

Citations

0
Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines DOI Creative Commons
Mohan Liu, Yusi Wang, Yi-Bing Zhang

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2025, Volume and Issue: 10(1)

Published: March 10, 2025

Abstract The ability of small nucleic acids to modulate gene expression via a range processes has been widely explored. Compared with conventional treatments, acid therapeutics have the potential achieve long-lasting or even curative effects editing. As result recent technological advances, efficient delivery for therapeutic and biomedical applications achieved, accelerating their clinical translation. Here, we review increasing number classes most common chemical modifications platforms. We also discuss key advances in design, development application each platform. Furthermore, this presents comprehensive profiles currently approved drugs, including 11 antisense oligonucleotides (ASOs), 2 aptamers 6 siRNA summarizing modifications, disease-specific mechanisms action strategies. Other candidates whose trial status recorded updated are discussed. consider strategic issues such as important safety considerations, novel vectors hurdles translating academic breakthroughs clinic. Small produced favorable results trials address previously “undruggable” targets, suggesting that they could be useful guiding additional candidates.

Language: Английский

Citations

0
Robust anti-tumor immunity through the integration of targeted lipid nanoparticle-based mRNA nanovaccines with PD-1/PD-L1 blockade DOI Creative Commons

Chengyan Jin,

Yan Zhang, Baofeng Li

et al.

Materials Today Bio, Journal Year: 2024, Volume and Issue: 27, P. 101136 - 101136

Published: June 22, 2024

Tumor mRNA vaccines present a personalized approach in cancer immunotherapy, encoding distinct tumor antigens to evoke robust immune responses and offering the potential against emerging variants. Despite this, clinical advancement of has been hampered by their limited delivery capacity inefficient activation antigen-presenting cells (APCs). Herein, we employed microfluidics technology engineer mannose-modified lipid-based nanovaccines for specifically targeting APCs. The encapsulation process efficiently entrapped cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) agonist along with antigens. targeted (TNVs) exhibited narrow particle size distribution, ensuring consistent efficient delivery. These TNVs significantly enhanced gene expression mRNA, facilitating antigen presentation activation. When compared non-targeted nanovaccines, outperformed terms Furthermore, combination anti-PD-L1 antibodies elicited synergistic anti-tumor effect. This was attributed antibodies' ability overcome suppression cells. Our findings suggest that treatment most memory results indicate integrating checkpoint inhibitors or other immunostimulatory agents may be crucial enhancing response.

Language: Английский

Citations

3